«Another potential application is biodefense, where eCAPs may be used as a rapid postexposure aerosol treatment in individuals after exposure to
aerosolized pathogens, where the goal of immediate treatment would be to rapidly reduce bacterial dose from a lethal to a nonlethal or subclinical level,» says Montelaro.
Aerosolizing the pathogen — so that it can be released and inhaled by a large number of people — is an obvious approach, but this is difficult to do, not least because many infectious agents can't survive long outside a host.
Not exact matches
In general, the risk of aerosol transmission increases with proximity and duration of exposure to the source; however, once
aerosolized, certain
pathogens may remain infective over long distances, depending on particle size, the nature of the
pathogen, and such environmental factors as temperature and humidity.3